MicroRNA-211-5p as a Biomarker in Early Detection of Uremic Vascular Calcification among Patients with End‐Stage Renal Disease

Liu, Xiao; Pan, Wei‐Ping; Zhang, Huiting; Li, Ling; Xiao, Hui

doi:10.56434/j.arch.esp.urol.20227508.103

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through ROC analysis, we uncovered that serum CDC42 > 1.025 was conducive to differentiating uremia patients with VC from uremia patients without VC (AUC: 0.7374, sensitivity: 83.58%, specificity: 56.76%), and serum CDC42 > 1.280 was effective in the diagnosis of VC progression (AUC: 0.7004, sensitivity: 73.33%, specificity: 68.18%). Compared with previously validated biomarkers, such as miR-211-5p (AUC: 0.889, sensitivity: 81.2%, specificity: 84.4%) [ 38 ] and osteoprotegerin (AUC: 0.79, sensitivity: 91.7%, specificity: 59.0%) [ 39 ], CDC42, though does not outperform in the prediction of CKD-related VC, has additional capacity to predict whether the severity of VC may be increased in the following 2 years. Moreover, CDC42 was evidenced as an independent risk factor for VC incidence ( P = 0.011, OR = 4.427, 95%CI = 1.401–13.986) and progression ( P = 0.003, OR = 4.703, 95%CI = 1.694–13.059).…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of serum CDC42 in the prediction of uremic vascular calcification incidence and progression

Pan

et al. 2023

Libyan Journal of Medicine

View full text Add to dashboard Cite

Vascular calcification (VC) is prevalent in uremia patients, lacking effective molecular biomarkers. This study was conducted to explore the role of serum cell division cycle 42 (CDC42) in the diagnosis of uremic VC incidence and progression. We enrolled 104 uremia patients and selected arcus aortae calcification (AAC) as the outcome phenotype. Levels of CDC42, 1,25-dihydroxy vitamin D (1,25(OH) 2 -D), fibroblast growth factor-23 (FGF-23), and other laboratory parameters in the blood were measured. The receiver operator characteristic curve, the Pearson test, and the multivariate Logistic regression were used for the analysis of CDC42 diagnostic values, correlation analysis, and screening of VC risk factors, respectively. CDC42 was higher in the serum of uremia patients with VC and elevated with the increase in AAC level. Serum CDC42 level>1.025 was predictive of VC incidence with 83.58% sensitivity and 56.76% specificity, and CDC42 level>1.280 was predictive of VC progression with 73.33% sensitivity and 68.18% specificity. Serum CDC42 was positively correlated with 1,25(OH) 2 -D and FGF-23. Uremia patients with higher serum CDC42 had a higher probability of VC incidence and progression. Generally, serum CDC42 helped the diagnosis of uremic VC incidence and progression and was an independent risk factor for uremic VC progression.

show abstract

Section: Discussionmentioning

confidence: 99%